Unknown

Dataset Information

0

Conformation-selective ATP-competitive inhibitors control regulatory interactions and noncatalytic functions of mitogen-activated protein kinases.


ABSTRACT: Most potent protein kinase inhibitors act by competing with ATP to block the phosphotransferase activity of their targets. However, emerging evidence demonstrates that ATP-competitive inhibitors can affect kinase interactions and functions in ways beyond blocking catalytic activity. Here, we show that stabilizing alternative ATP-binding site conformations of the mitogen-activated protein kinases (MAPKs) p38? and Erk2 with ATP-competitive inhibitors differentially, and in some cases divergently, modulates the abilities of these kinases to interact with upstream activators and deactivating phosphatases. Conformation-selective ligands are also able to modulate Erk2's ability to allosterically activate the MAPK phosphatase DUSP6, highlighting how ATP-competitive ligands can control noncatalytic kinase functions. Overall, these studies underscore the relationship between the ATP-binding and regulatory sites of MAPKs and provide insight into how ATP-competitive ligands can be designed to confer graded control over protein kinase function.

SUBMITTER: Hari SB 

PROVIDER: S-EPMC4123212 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Conformation-selective ATP-competitive inhibitors control regulatory interactions and noncatalytic functions of mitogen-activated protein kinases.

Hari Sanjay B SB   Merritt Ethan A EA   Maly Dustin J DJ  

Chemistry & biology 20140403 5


Most potent protein kinase inhibitors act by competing with ATP to block the phosphotransferase activity of their targets. However, emerging evidence demonstrates that ATP-competitive inhibitors can affect kinase interactions and functions in ways beyond blocking catalytic activity. Here, we show that stabilizing alternative ATP-binding site conformations of the mitogen-activated protein kinases (MAPKs) p38α and Erk2 with ATP-competitive inhibitors differentially, and in some cases divergently,  ...[more]

Similar Datasets

| S-EPMC7700871 | biostudies-literature
| S-EPMC4765092 | biostudies-literature
| S-EPMC11253600 | biostudies-literature
| S-EPMC1373668 | biostudies-literature
| S-EPMC1560367 | biostudies-literature
| S-EPMC3004264 | biostudies-literature
| S-EPMC10972564 | biostudies-literature
| S-EPMC10515847 | biostudies-literature
| S-EPMC3330201 | biostudies-literature
| S-EPMC3202601 | biostudies-literature